Reuters logo
1 年前
BRIEF-Cyclacel Pharmaceuticals reports updated data from DNA damage response program on seliciclib, sapacitabine combination
2016年6月6日 / 下午2点32分 / 1 年前

BRIEF-Cyclacel Pharmaceuticals reports updated data from DNA damage response program on seliciclib, sapacitabine combination

June 6 (Reuters) - Cyclacel Pharmaceuticals

* Cyclacel pharmaceuticals reports updated data from dna damage response program on seliciclib and sapacitabine combination in patients with solid tumors

* Antitumor activity demonstrated in a subgroup of 45 patients with breast, ovarian and pancreatic cancers who tested positive for brca mutations Source text for Eikon: (Bengaluru Newsroom; +1 646 223 8780; )

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below